Authors
Olfat Ahmad, Felipe D'Almeida Costa, Wouter R L Hendrickx, Ahmed Gilani, Vaishali Suri, Nabe Al-Hasnawi, Monique Stenzel, Martin Lablans, Syed Ather Enam, Shahenda El-Naggar, Horacio Martinetto, Gustavo Sevlever, Blanca Diez, Maysa Al-Hussaini, Sith Sathornsumetee, Thidathip Wongsurawat, Ludi Dhyani Rahmartani, Naureen Mushtaq, Erdener Ozer, Christophe M Raynaud, Paromita Roy, Sushant S Vinarkar, Rimpa Basu Achari, Pablo Zoroquiain, Roger Gejman, Cristovam Scapulatempo Neto, Leslie D Kulikowski, João Victor Alves de Castro, Luiz Gustavo Dufner-Almeida, Beatriz Wolff, Yuri Reis Casal, Khurram Minhas, Andréa Maria Cappellano, Stefan Hamelmann, Mohamed S Abdelbaki, Lorena V Baroni, Abrar Al-Masamreh, Abdlrahman Eswed, Ute Bartels, Dominik Sturm, Martin Sill, David T W Jones, Areeba Patel, Felix Sahm, Stefan M Pfister, MNP Outreach Consortium
Published in
Neuro-oncology. Oct 12, 2026. Epub Oct 12, 2026.
Abstract
Central nervous system (CNS) tumors pose a major global health challenge, particularly in low- and middle-income countries (LMICs), where outcomes remain disproportionately poor. The global CONCORD-3 study (Lancet Oncology) highlighted stark disparities in five-year survival (2010-2014): from ∼15% in Thailand to 46% in Japan among adults, and from ∼ 80% in Denmark to < 40% in Brazil among children. Limited access to specialized pathology and molecular diagnostics in LMICs results in diagnostic uncertainty and restricted treatment options. DNA methylation-based tumor classification, has revolutionized CNS tumor diagnosis and got incorporated into the 2021 world health organization (WHO) CNS5 classification. However, its accessibility, feasibility, and performance in LMICs remain insufficiently explored. Importantly, several ethnic groups common in LMICs are underrepresented in current reference datasets. To address this, the Molecular Neuro-Pathology (MNP) Outreach Consortium was launched in Heidelberg, partnering with 11 countries-including nine LMICs from Asia, Africa, and South America. Early insights from Brazil, Jordan and Argentina, show methylation profiling changing diagnosis in up to 25% cases. Gains are greatest in pediatric and adolescents and young adults (AYA) populations. In addition, it reduced the designation of not otherwise specified (NOS) from 51.3% to 8.8% across 476 CNS tumours in Brazil.
PMID:
42861759
Bibliographic data and abstract were imported from PubMed on 12 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 14
- Comments 0